120 related articles for article (PubMed ID: 15119047)
1. Anti-IgE therapy combined with specific immunotherapy: pro.
Wahn U; Hamelmann E
Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 2003; (94):269-71. PubMed ID: 15119047
[No Abstract] [Full Text] [Related]
2. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children.
Rolinck-Werninghaus C; Hamelmann E; Keil T; Kulig M; Koetz K; Gerstner B; Kuehr J; Zielen S; Schauer U; Kamin W; Von Berg A; Hammermann J; Weinkauf B; Weidinger G; Stenglein S; Wahn U;
Allergy; 2004 Sep; 59(9):973-9. PubMed ID: 15291906
[TBL] [Abstract][Full Text] [Related]
3. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis.
Keskin O; Tuncer A; Adalioglu G; Sekerel BE; Saçkesen C; Kalayci O
Pediatr Allergy Immunol; 2006 Sep; 17(6):396-407. PubMed ID: 16925684
[TBL] [Abstract][Full Text] [Related]
4. Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis.
Bez C; Schubert R; Kopp M; Ersfeld Y; Rosewich M; Kuehr J; Kamin W; Berg AV; Wahu U; Zielen S
Clin Exp Allergy; 2004 Jul; 34(7):1079-85. PubMed ID: 15248853
[TBL] [Abstract][Full Text] [Related]
5. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously.
Kamin W; Kopp MV; Erdnuess F; Schauer U; Zielen S; Wahn U
Pediatr Allergy Immunol; 2010 Feb; 21(1 Pt 2):e160-5. PubMed ID: 19732370
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children.
Valovirta E; Jacobsen L; Ljørring C; Koivikko A; Savolainen J
Allergy; 2006 Oct; 61(10):1177-83. PubMed ID: 16942565
[TBL] [Abstract][Full Text] [Related]
7. Omalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential in vitro parameter to monitor therapeutic effects.
Kopp MV; Stenglein S; Kamin W; Friedrichs F; von Berg A; Zielen S; Hamelmann E; Wahn U; Kuehr J
Pediatr Allergy Immunol; 2007 Sep; 18(6):523-7. PubMed ID: 17680911
[TBL] [Abstract][Full Text] [Related]
8. Dose dependence of immunological response to sublingual immunotherapy.
Marcucci F; Sensi L; Di Cara G; Incorvaia C; Frati F
Allergy; 2005 Jul; 60(7):952-6. PubMed ID: 15932387
[TBL] [Abstract][Full Text] [Related]
9. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis.
Casale TB; Busse WW; Kline JN; Ballas ZK; Moss MH; Townley RG; Mokhtarani M; Seyfert-Margolis V; Asare A; Bateman K; Deniz Y;
J Allergy Clin Immunol; 2006 Jan; 117(1):134-40. PubMed ID: 16387596
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for allergic rhinitis.
Adkinson NF
N Engl J Med; 1999 Aug; 341(7):522-4. PubMed ID: 10441610
[No Abstract] [Full Text] [Related]
11. Efficacy and tolerability of high dose sublingual immunotherapy in patients with rhinoconjunctivitis.
Worm M
Eur Ann Allergy Clin Immunol; 2006 Dec; 38(10):355-60. PubMed ID: 17274520
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis.
Racine-Poon A; Botta L; Chang TW; Davis FM; Gygax D; Liou RS; Rohane P; Staehelin T; van Steijn AM; Frank W
Clin Pharmacol Ther; 1997 Dec; 62(6):675-90. PubMed ID: 9433396
[TBL] [Abstract][Full Text] [Related]
13. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U;
Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798
[TBL] [Abstract][Full Text] [Related]
14. Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually.
Panzner P; Petrás M; Sýkora T; Lesná I
Respir Med; 2008 Sep; 102(9):1296-304. PubMed ID: 18585908
[TBL] [Abstract][Full Text] [Related]
15. The effects of allergen-specific immunotherapy on polymorphonuclear leukocyte functions in patients with seasonal allergic rhinitis.
Soyoğul Gürer U; Büyüköztürk S; Palandüz S; Rayaman E; Colakoglu B; Cevikbaş A
Int Immunopharmacol; 2005 Apr; 5(4):661-6. PubMed ID: 15710335
[TBL] [Abstract][Full Text] [Related]
16. The use of grass pollen-specific immunotherapy among grass pollen allergic rhinitis in the general population.
Linneberg A; Bødtger U
Allergy; 2007 Jul; 62(7):825-6. PubMed ID: 17573735
[No Abstract] [Full Text] [Related]
17. Sublingual immunotherapy.
Corrigan C
J Allergy Clin Immunol; 2007 Feb; 119(2):515; author reply 515-7. PubMed ID: 17187850
[No Abstract] [Full Text] [Related]
18. Anti-IgE antibody therapy.
MacGlashan D
Clin Allergy Immunol; 2002; 16():519-32. PubMed ID: 11577557
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of immunotherapy in allergic rhinitis.
Jayasekera NP; Toma TP; Williams A; Rajakulasingam K
Biomed Pharmacother; 2007 Jan; 61(1):29-33. PubMed ID: 17189678
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the seasonal IgE increase to Dactylis glomerata by daily sodium chloride nasal-sinus irrigation during the grass pollen season.
Subiza JL; Subiza J; Barjau MC; Rodríguez R; Gavilán MJ
J Allergy Clin Immunol; 1999 Sep; 104(3 Pt 1):711-2. PubMed ID: 10482855
[No Abstract] [Full Text] [Related]
[Next] [New Search]
